TX-MAVENIR
27.2.2020 15:02:27 CET | Business Wire | Press release
Mavenir, the industry's leading end-to-end cloud-native network software provider for CSPs, has announced a business partnership with Turkcell, Turkey’s leading digital operator. The two companies, together, will test and deploy OpenRAN vRAN within the Turkcell Group, initially in their home market, Turkey.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200227005534/en/
The partnership will start directly with fully containerized CU/DU and Open FH with Split 7.2 in trial and planned deployments, which will become a first in the industry. Virtual RAN solution will be deployed on Turkcell Telco Cloud and it will be first workload that will be going live on Turkcell Edge Cloud.
Mavenir’s innovative, award winning OpenRAN vRAN solution centralizes baseband processing in cloud-native virtualized baseband units (vBBU) and exploits fronthaul over ethernet between vBBU and multiple remote radio units (RRU). The Mavenir vRAN architecture and platform can support 4G as well as both the NSA and SA implementations of 5G NR.
Mikael Rylander, SVP/GM Radio Access Products stated, “We are excited to be working with Turkcell, a thought leader for OpenRAN, again proving that OpenRAN solutions are a critical step in expanding the supply base and increasing security for future mobile networks.”
With open interfaces, the solution has the flexibility to support various deployment scenarios – including functional split 2 for enterprises and split 2 & 7 for macro cells. It can also support massive MIMO, edge micro services and network slicing for 5G NR.
Gediz Sezgin, Turkcell CTO stated, “At Turkcell, we have reached more than 60% virtualization in our mobile core network. We already take great advantage of what virtualization has to offer and are willing to extend the benefits of virtualization coupled with open RAN for the next step in Turkcell’s Radio Access Network evolution. With its broad experience and expertise in RAN technologies and Network Virtualization, Turkcell will make great contribution for innovation on open vRAN towards 5G era. We are excited to take on and lead this journey.”
About Mavenir:
Mavenir is the industry's only end-to-end, cloud-native Network Software Provider focused on accelerating software network transformation and redefining network economics for Communications Service Providers (CSPs) by offering a comprehensive end-to-end product portfolio across every layer of the network infrastructure stack. From 5G application/service layers to packet core and RAN, Mavenir leads the way in evolved, cloud-native networking solutions enabling innovative and secure experiences for end users. Leveraging industry-leading firsts in VoLTE , VoWiFi , Advanced Messaging (RCS) , Multi-ID , vEPC and OpenRAN vRAN , Mavenir accelerates network transformation for more than 250+ CSP customers in over 140 countries, which serve over 50% of the world’s subscribers.
We embrace disruptive, innovative technology architectures and business models that drive service agility, flexibility, and velocity. With solutions that propel NFV evolution to achieve web-scale economics, Mavenir offers solutions to help CSPs with cost reduction, revenue generation and revenue protection. Learn more at mavenir.com.
Mavenir, the M logo, and CloudRange are trademarks owned by Mavenir Systems, Inc.
Copyright © 2020 Mavenir Systems, Inc. All Rights Reserved.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200227005534/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bial Announces Completion of Phase 2b ACTIVATE Study with BIA 28-6156 in GBA1-Associated Parkinson’s26.5.2026 08:00:00 CEST | Press release
Study Topline results will be released around the end of Q2 2026 BIA 28-6156 is being developed as a potential first-in-class disease-modifying therapy in GBA-PD Bial was present at the GBA1 conference and is currently attending the World Parkinson Congress Bial, an innovation-driven biopharmaceutical company focused on neurosciences and rare diseases, today announced the completion of the treatment period in its Phase 2b ACTIVATE study of BIA 28-6156 (pariceract) in patients with Parkinson’s disease (PD) who have a pathogenic mutation in the glucocerebrosidase 1 (GBA1) gene (GBA-PD). Upon completion of the 78-week double-blind treatment period and all scheduled safety follow-ups, data cleaning and analysis are currently ongoing. Topline results will be released around the end of Q2. A status report on the ACTIVATE study was presented in an oral presentation at the 3rd International GBA1 Meeting 2026. The team is currently attending the 7th World Parkinson Congress, taking place in Pho
Oticon Medical Introduces Ponto™ Instant, Expanding Non-Surgical Choice with Instant HearBand and Instant SoundConnector26.5.2026 07:00:00 CEST | Press release
Oticon Medical today announces its new non-surgical portfolio, Ponto Instant, designed to broaden access to bone conduction hearing and offer more choice for users and hearing care professionals. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260525771593/en/ Left: Instant HearBand, a discreet behind-the-head wearable solution that offers an alternative to Softband 5. Right: Instant SoundConnector, a small accessory fitted to a cap or other headwear, providing another non-surgical way to wear a Ponto sound processor. The Ponto Instant portfolio includes Softband 5, Oticon Medical’s established and trusted non-surgical solution, and now expands with the launch of Instant HearBand and Instant SoundConnector, further strengthening its wearable offering for children and adults who prefer a non-surgical solution. Instant HearBand: a discreet new wearable alternative As part of the new portfolio, Instant HearBand is introduced as
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom